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Summary.-Multiple myeloma is often associated with humoral immunodepression
in both man and mouse. When mice bearing the humorally immunodepressive
plasmacytomas TEPC-183 and SPQC-l1 were injected with SRBC, the rise of serum
haemolysins was significantly less than that of non-tumour-bearing mice. Mice with
the plasmacytomas MPC-ll and MOPC-315 have an antibody response similar to
normal mice when injected with SRBC. Following immunization, normal mice and
those bearing MPC-ll showed a 2- to 3-fold increase in total spleen lymphocytes.
Mice bearing TEPC-183 or SPQC-11, the plasmacytomas causing an impaired
antibody response, has significant increase in spleen lymphocytes under the same
conditions. Mice bearing MOPC-315 had a very high initial count of spleen lympho-
cytes, which did not further increase upon immune stimulation.
Incubation of lymphocytes from plasmacytoma-bearing mice with PHA did not
produce an increase in TdR incorporation and in some cases even caused a decrease
in TdR incorporation.
Lymphocytes from mice bearing TEPC-183, SPQC-11, and MOPC-315 incorporated
less TdR in response to LPS than did normal mice. On the other hand, mice bearing
MPC-ll incorporated about as much TdR as did normal mice following LPS stimula-
tion. Thus, the defect in the ability to respond to LPS in vitro correlated with the lack
of an increase of spleen lymphocytes in mice bearing these tumours following anti-
genic stimulation in vivo.
No immunodepressive properties of serum from mice with plasmacytoma could
be detected.
MULTIPLE mnyeloma, both in man (Fahey
etal., 1963; Cone andUhr, 1964; Dammaco
and Clausen, 1966) and the mouse (Smith
et al., 1960; Fahey and Humphrey, 1962;
Hirano et al., 1968; Zolla et al., 1974) often
produces a marked humoral immuno-
depression. Associated with this depressed
antibody response is the tendency of
patients with myeloma to fall victim to
infectious diseases (Fahey et al., 1963;
Zinneman and Wall, 1964; Scharff and
Uhr, 1965; Meyers et al., 1972). The
mechanism of this humoral immuno-
depression is the subject of considerable
controversy.
Hypotheses advanced to explain the
humoral immunodepression of myeloma
fall into two broad classes: those attribut-
ing it to a circulating immnunodepressive
factor, and those invoking a defect in the
antibody-producing cells themselves. Pro-
ponents of the existence of circulating
immunodepressive factors have suggested
that these may be viral R1NA (Heller et
al., 1973; Chen et al., 1975) or a chalone-
like substance (Tanapatchaiyapong and
Zolla, 1974). The role of the myeloma
protein in the causation of this humoral
immunodepression is questionable, since
there is no correlation between the type or
quantity ofthe monoclonal protein and the
impairment of the antibody response
(Fahey et al., 1963). Plasmacytomas that
do not secrete any monoclonal immuno-
globulins can also cause humoral immuno-
depression (Zolla, 1972). Other authorsI. BRUS, J. BRENT AND V. P. HOLLANDER
have presented evidence suggesting a
defect at the cellular level (Jones and
McFarlane, 1975; Padarathsingh et al.,
1976). Our preliminary studies have re-
vealed that, unlike normal mice, those
bearing certain plasmacytomas do not
respond to antigenic stimulation with an
increase in spleen lymphocytes (Brus et al.,
1975). This phenomenon could be due to
an impaired recall of lymphocytes to the
spleen, or alternatively, an inability of
lymphocytes to proliferate in response to
stimulation.
The present studies were undertaken to
determine whether the lack of increase in
spleen lymphocytes following immuniza-
tion with sheep red blood cells (SRBC) is
related to an inability to respond to
mitogenic stimulation. This was evaluated
using mitogens specific for B- and T-cell
subpopulations. The results presented here
indicate a cellular defect in the lympho-
cytes of plasmacytoma-bearing mice.
MATERIALS AND METHODS
Tumours.-The following mouse myelomas,
all of BALB/c origin, were used: TEPC-183
and SPQC-11, both of which cause an im-
paired antibody response, and MOPC-315
and MPC-11, which do not cause humoral
immunodepression. TEPC-183 produces an
IgM (k) protein, SPQC-11 and MPC-11
both produce an IgG2b (k) protein, and
MOPC-315 produces an IgA (k) protein.
Immunoglobulin production ofthese tumours
was monitored by immunoelectrophoresis.
These tumours were maintained by s.c.
inoculation of 0-15 ml of tumour-cell suspen-
sion into BALB/c female mice. TEPC-183
and SPQC-11 were kindly given to us by
Dr Susan Zolla-Pazner of the V. A. Hospital,
New York University Medical School;
MOPC-315 was given to us by Dr Herman
Eisen of the Massachusetts Institute of
Technology; and MPC-11 was a gift from
Dr Matthew Scharff of the Albert Einstein
School ofMedicine.
Serum.-Blood was collected from the
axillary artery. After clotting, the serum
was collected by centrifugation and used
immediately.
Immunization.-Mice were immunized
with i.p. injection of 0-15 ml of 25% SRBC,
18-21 days after tumour inoculation. Control
mice were given equivalent volumes of
sterile saline. Four and one-half days after
immunization, at the peak of the primary
immune response, serum was collected for
haemolysin determination. At this time
the tumours ranged from 10 to 25% of total
body weight. Tumours outside this range
were not included in this study. The haemo-
lysins were determined by a microtitre
technique in which serial 2-fold dilutions
of serum, heated at 56°C for 20 min, were
made in 0-25 ml of 0-9% NaCl solution
at initial dilution of 1: 1. After addition
of equal volumes of 1.5% SRBC and guinea-
pig complement diluted 1: 5 with 0.9%
saline, the mixtures were incubated at
37°C for 30 min and then at 4°C overnight.
Thehighest dilution showing complete haemo-
lysis was used as the haemolysin titre.
Total spleen lymphocyte evaluation.-
Spleens from normal BALB/c mice and
plasmacytoma-bearing mice were removed
and weighed. The cells were then gently
squeezed out of the spleen capsule with a
plastic syringe plunger into a sterile cold
RPMI-1640 medium supplemented with peni-
cillin (100 ,ug/ml), streptomycin (50 ,tg/ml)
and glutamine (3 ,uM/ml). The cells were
passed several times through a 20-gauge
needle to eliminate clumps, and washed with
cold medium. The spleen-cell suspension
was layered on a Hypaque-Ficoll gradient
(1 078 density) and centrifuged for 40 min
at room temperature at 400g. Cells were
removed from the interphase with a Pasteur
pipette and washed twice with medium at
100g for 10 min. Smears of these cells,
stained with WVright's stain, showed that
94-98% of this population were morpho-
logically identifiable as lymphocytes. The
remaining fraction of cells were monocytes.
Similar results were obtained by examination
of these cells by phase microscopy, where
lymphocytes were differentiated from mono-
cytes by the ability of the latter to ingest
latex particles. The lymphocyte count and
viability were determined on a Biophysics
Cytograf 6300A and expressed as total
lymphocyte count per spleen (TLC/S). The
viability ranged from 89 to 96%. Imprints
and frozen sections of the spleens were taken
and stained with Wright's or haematoxylin-
eosin (HE) stain, respectively.
Mitogenic 8timulation.-Lymphocytes were
prepared as previously described. Pooled
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lymphocytes isolated from 5-8 spleens in
each group were used. All cultures were
set up in triplicate in flat-bottomed micro-
plates (3040 Microtest II, Falcon Plastics).
The final culture volume was 0-2 ml con-
taining 106 lymphocytes per well. PHA-P
was obtained from Difco Laboratories, De-
troit, Mich. (48232). The final concentration
of PHA-P was 5 jig/well. This dose gave
optimal stimulation as determined by a
dose-response curve.
Lipopolysaccharide LPS (E. coli 055: B5)
from Difco Laboratories was used in a final
concentration of 30 ,ug/well, this dose gave
the optimal stimulation.
All wells containing PHA-P were supple-
mented with 5% fresh, decomplemented
Millipore-filtered pooled mouse serum. The
optimal LPS response was obtained without
addition of serum. Serum was only used
with this mitogen when comparing the
effect of serum from normal and plasma-
cytoma-bearing mice.
Microplates were incubated for 48 h at
37°C in 5% CO2 and 95% air. Four hours
before incubation was terminated, the cells
were pulsed with 1 ,uC of3H-TdR (methyl 3H)
from Schwarz/Mann, Orangeburg, N.Y., sp.
act. 1-9 Ci/mM. Cells were harvested in a
MASH harvester (Rockefeller University
Workshop). The filter papers on which
the cells were harvested were dried, placed
in vials with Bray's scintillation fluid and
counted in a Packard liquid scintillation
counter. Results are expressed both as the
mean of ct/min of triplicate cultures+s.e.
mean and as stimulation index (ct/min
stimulated/ct/min unstimulated).
Statistical analysis.-Statistical analysis
was performed using Student's t test.
RESULTS
Effect of mouse plasmacytomao n spleen
lymphocytes
After immunization, non-tumour-bear-
ing mice showed >100% increase in
TLC/S compared to mice injected with
saline only (Table I). The haemolysin
titres of immunized normal mice were
always in the range of 6-10 (log 2). Mice
bearing plasmacytomas TEPC-183 and
SPQC-l1 show a markedly impaired anti-
body response. Associated with this im-
munodepression is a lack of an increase in
TLC/S following antigen stimulation.
Mice bearing tumour MPC-I1, which
does not interfere with the antibody res-
ponse, showed a marked increase in
TLC/S following immunization.
Mice bearing the plasmacytoma MOPC-
315 demonstrate a normal or sometimes
TABLE I.-Effect ofImmunization with Sheep Red Blood Cells (SRBC) on Total
Lymphocyte Counts/Spleen (TLC/S) and Haemolysin Titres*
Tumour Treatment
None ~~Saline
None sSRBC
TEPC-183 Saline SRBC
Saline
None SRBC
SPQC-ll Saline
PQC-11 SRBC
Saline
None SRBC
MPC-ll ~ Saline
MPC-11 SRBC
None ~~Saline
None sSRBC
MOPC-315 Saline SRBC
Number of TLC/S x 10-6
mice mean± s.e.
8
8
10
11
7
6
4
7
4
4
8
8
6
6
8
9
5-8±1 1
16-3±2-7
3-4±0*6
5-8±0 -9
7-5±1 *3
16-1±3-7
5-1±2-2
3 *2±0-9
9-2+1 0
21 - 2+3 - 7
17 -8±2 * 7
44- 8±9 -4
7-92 *4
16 -0+2 * 6
28-6+8-7
26-5±664
Haemolysin
p titre (log2)
0
<0 *005 8 - 9+0 * 6
0
N.S. 4-6+0-3
0
<0 05 7 0+0 3
0
N.S. 4-6+0-3
0
<0-025 8-5+1-5
0
<0-025 7 5+0 5
0
<0 *05 6 - 8+1*1
0
N.S. 6-8+0-7
* TLC/S were determined 4 days after i.p. injection of 0 * 15 ml of 0 * 5% SRBC. Immunizations were done
18-21 days after s.c. tumour inoculation. Lymphocytes were isolated by Ficoll-Hypaque density centrifuga-
tion and quantitated with a Biophysics Cytograf 6300 A as described in Materials and Methods.
Haemolysin titres were determined as described in Materials and Methods.
I
II
III
IV
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TABLE II.-PHA Stimulation ofLymphocytesfrom Normal and Plasmacytoma-
bearing Mice
Lymphocytes from BALB/c
mice bearing:
No tumour
MOPC-315
No tumour
MPC-ll
No tumour
SPQC- 1
No tumour
TEPC-183
ct/minx 10-3*
Unstimulated Stimulated
Mean± s.e.
0-81±0 47
3-34±1 11
0-97±0-58
4-76±1 -81
0-32±0- 14
4 06±1 -28
0-39±0-15
2 -56±1 43
7-33±3 -52
1 -66±1 - 16
10-25±3 - 10
7 93±4-75
4 2242-97
0 97±0-82
4-91±2-78
3-01±2-11
Stimulation index:
ct/min stimulated/ct/min
unstimulated
Mean±s.e.
10 17±3 349
0 67±0 48
16-52±3 -43
1 30±0 58
9-67± 2-86
0 20±0 11
11 -37±2-39
0 74±0 27
* 106 lymphocytes were incubated in 0-2 ml of RPMI 1640 supplemented with 50% decomplemented
normal mouse serum for 48 h at 37°C in an atmosphere of 5% CO2 and 95% air. Cells were stimulated with
5 ,tg PHA/0 -2 ml/well. 4 h before the termination of incubation, the cells were pulsed with 3H-TdR. Cells
for each experiment were from a pool oflymphocytes derived from 5-8 mice. Each experiment consisted of 3
replicate cultures for each condition. Figures quoted are the mean from 4 experiments.
TABLE III. LPSStimulation ofLymphocytesfrom Normal andPlasmacytoma-
bearing Mice
Lymphocytes from
BALB/c mice No. of
bearing: experiments
No tumour 2
MOPC-315
No tumour 8
MPC-ll
No tumour
SPQC- 1I
No tumour 6
TEPC-183
ct/min x 10-3
A A
Unstimulated
Mean±s.e.
0-51±0 29
2 07±0-31
1 -13±0-34
3 -08±0 - 80
1 -36±0 -42
2-34±0-67
0 84±0 40
1 36±0 60
Stimulated
8-15+4-48
5*45±3 *88
14-07±2 *24
15 - 77±2 -48
13-86±3-42
6-48±2*72
11*774-3 *74
5-69±1*76
Stimulation index:
ct/min stimulated/ct/min
unstimulated
Mean± s.e.
16-00±0-20
2-97±2-32
16-98±2-93
7 -08 1 -40
11 45±2 27
3 08±1 32
17-59±3 -85
6-42±1-21
Experiments were performed as described for Table II except that serum was not used. LPS was added to a
concentration of 30 ,tg/0 * 2 ml/well.
even greater than normal antibody res-
ponse. Spleens from mice bearing this
tumour have an unusually high number of
lymphocytes before immunization. Injec-
tion of SRBC does not further elevate the
TLC/S in this tumour.
Mice bearing plasmacytomas had mark-
edly enlarged spleens, ranging from 160 to
690 mg. Normal mouse spleens averaged
110 mg. However, there was no correla-
tion between spleen lymphocyte count and
spleen weight. No metastatic tumour was
seen in the spleens upon macroscopic
examination. Imprints and frozen sections
of spleens from all plasmacytoma-bearing
mice showed the presence of some tumour
cells. However, the number of tumour
cells present was negligible compared to
the total lymphocytes. The splenomegaly
oftumour-bearing mice correlated with an
increase in total leucocytes, erythrocytes
and platelets in their spleens.
PHA stimulation of lymphocytes
Lymphocytes from all plasmacytoma-
bearing mice showed a markedly impaired
ability to respond to PHA relative to those
from normal mice. As shown in Table II,
the net amount of TdR incorporated by
lymphocytes from tumour-bearing mice
was less than that of cells from normal
mice. Lymphocytes from both MOPC-315
and SPQC-11 showed an actual decrease
in TdR incorporation relative to non-
stimulated lymphocytes from mice bearing
these tumours. Lymphocytes from mice
with TEPC-183 showed no difference
between stimulated and unstimulated
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TABLE IV.-Effect of Serum from Normal and Plasmacytoma-bearing Mice on PHA
Stimulation of Lymphocytes from BALB/c Mice
ct/min x 10-3 Stimulation index:
, - A ct/min stimulated/ct/min
Serum from No. of Unstimulated Stimulated unstimulated
1-00±0-37
1 -13±0-34
0-86±0-46
0-76±0-36
0-35±0-09
0-28±0 0-08
0-44±0-14
0- 82±0 -49
Mean±s.e.
11 -16±3-45
11-78±3-36
9 -41 ±2 -54
10-52±3 -36
4-33±1 -92
2 -63±1 -22
7 - 12 ± 2 - 79
8-17±4-21
Mean±s.e.
11 87+1-93
10-74±2-21
16 06±2 70
18 - 74±3 -26
10-17±2-00
8- 72± 1 -93
12 -38±1 -93
8-67±2-97
The experiments were performed as described for Table II. The cells were incubated with either 5%
normal mouse serum or 5% serum from tumour-bearing mice.
TABLE V.-Effect of Serum from Normal and Plasmacytoma-bearing Mice on LPS
Stimulation of Lymphocytes from BALB/c Mice
ct/min x 10 -3 Stimulation index:
Serum from No. of
mice bearing: experiments
No tumour 3
MOPC-315
No tumour 8
MPC-11
No tumour 4
SPQC-11
No tumour 6
TEPC-183
Unstimulated
2-21±0-93
1 -73±0-52
1-41±0-42
1 -17±0- 31
1-55±0-43
0-88±0-09
1 -28±0-50
1 -08±0 -52
Mean±s.e.
Stimulated
9-59±3-33
12-36±3 -02
5-35±1 -33
7-82±2 -31
6-51±2-09
5-74±1 -75
5- 12±2 2-00
6-78±2-60
ct/min stimulated/ct/min
unstimulated
Mean±s.e.
5-04±0-98
7 -72±1-12
4- 19±0-62
6-22±0-56
4-08±0 -53
6-28±1 -46
4-06±0-46
7 - 69± 1 - 66
These experiments were performed as described for Table II except that 5% normal mouse serum or 5%
serum from tumour-bearing mice was used.
counts. Lymphocytes from mice bearing
MPC-I had lower net TdR incorporation
than did lymphocytes from non-tumour-
bearing mice.
LPS stimulation of lymphocytes
When stimulatedwithLPS,lymphocytes
from mice bearing MOPC-315, SPQC-11
and TEPC-183 had a lower net TdR
incorporation than did those from normal
mice. However,lymphocytesfromMPC- 11-
bearing mice incorporated the same net
amount of TdR as did lymphocytes from
normal mice.
As shown in Tables II and III, all
unstimulated lymphocytes from plasma-
cytoma-bearing mice showed higher basal
TdR incorporation than did lymphocytes
from normal BALB/c mice. It was noted
that unusually high unstimulated counts
were seen in 3 experiments where lympho-
cytes contained much greater than normal
contamination of MOPC-315 tumour cells
(not shown in tables). For example,
lymphocytes from mice bearing MOPC-315
with greater than usual contamination of
tumour cells in the spleen showed 105
counts per well in the absence of mitogen.
Effect of serum on the mitogenic response of
lymphocytes
Tables IV and V show that incubation
oflymphocytes from normal BALB/c mice
with serum from plasmacytoma-bearing
mice did not impair the response of
lymphocytes to either PHA or LPS. In
fact, sera from plasmacytoma-bearing
mice caused a slight but nonsignificant
increase of LPS stimulation, as evidenced
by the net increase of TdR incorporated.
DISCUSSION
Mice bearing plasmacytomas and pat-
ients with multiple myeloma often show
mice bearing:
No tumour
MOPC-315
No tumour
MPC-ll
No tumour
SPQC- 11
No tumour
TEPC-183
experiments
10
5
6
9
1-
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an impairment of antibody production
after antigenic stimulation (Marks, 1953;
Lawson et al., 1955). Several studies have
shown that mice bearing the plasmacyto-
mas TEPC-183 and SPQC-11 have a
markedly impaired primary response, as
shown by decreased number of plaque-
forming cells after immunization with
SRBC (Zolla, 1972; Zolla et at., 1974).
In our own studies, normal mice show
an increase of both TLC/S and antibody
titres after SRBC injection (Table I).
However, the plasmacytomas TEPC-183
and SPQC-1 1 cause a depressed antibody
response and lack of spleen lymphocyte
increase after SRBC immunization. As
shown in Table I, plasmacytomas MOPC-
315 and MPC-11 do not affect the anti-
body response. Mice bearing MPC- 1 show
lymphocyte counts similar to that of
normal mice after SRBC immunization.
However, in mice bearing plasmacytoma
MOPC-315, stimulation does not result in
further increase of their already high un-
stimulated lymphocyte counts.
In order to determine whether the lack
of an increase of spleen lymphocytes
following immunization of mice bearing
the humorally immunodepressive plas-
macytomas is due to inability to prolifer-
ate when stimulated, we evaluated their
response to mitogens specific for B- and T-
cell subpopulations. Mitogenic response
can be evaluated by stimulation index,
total number ofcountsincorporated, orthe
net increase in the number of counts
following mitogenic stimulation. It is
important to stress that stimulation
indices are only useful when comparing the
stimulation of similar populations of cells.
Under these conditions, the denominator
(ct/min unstimulated) remains constant,
and the only variable is the numerator
(ct/min stimulated). However, in our
studies, marked differences in the TdR
incorporation of unstimulated cultures
make the stimulation index an ambiguous
parameter. A more useful parameter is the
net increase (ct/min stimulated-ct/min
unstimulated) inTdRincorporation follow-
ing mitogenic stimulation. While our
results (Tables II-V) are given as all 3 of
the parameters listed above, interpreta-
tions were made using the net increase in
counts.
PHA is known to be a T-cell mitogen in
mice (Dukor and Dietrich, 1967; Doenhoff
et al., 1970; Andersson and Blomgren,
1971; Blomgren and Svermyr, 1971). Our
data on the effect of PHA on lymphocytes
of plasmacytoma-bearing mice show a
marked decrease in net TdR incorporated
following mitogenic stimulation. Studies
by Zolla-Pazner, Sullivan and Richardson
(1976) on lymph-node cells from plasma-
cytoma-bearing mice, show that the
response of these cells to PHA does not
differ dramatically from that of normal
mice. However, their data on spleen cells
from one line of plasmacytoma-bearing
mice revealed an impairment of the
response to PHA similar to those repeated
here by us. These studies are in agreement
with the preliminary data on mitogenic
response of spleen cells from plasma-
cytoma-bearing mice as reported by
Padarathsingh et al. (1976). Peripheral
lymphocytes from patients with multiple
myeloma also show a depressed response to
PHA (Jones and MacFarlane, 1975). It
should be noted that the impaired res-
ponse to PHA may not be related to the
humoral immunodepression associated
with myelomas, since our data indicate
that the response to this mitogen was
depressed even in the lymphocytes from
plasmacytoma-bearing mice capable of a
normal antibody response to SRBC, a
T-cell-dependent antigen.
B-lymphocyte function was evaluated
with LPS, a B-cell mitogen (Peavy et al.,
1970; Gery et al., 1972). The results of
LPS stimulation of lymphocytes correlate
with the data presented on lymphocyte
proliferation after immunization with
SRBC. Immunization of mice bearing
MOPC-315, TEPC-183, and SPQC-11 does
not result in an increase in total spleen
lymphocytes, nor do mice bearing these
tumours respond normally to LPS stimu-
lation. Lymphocytes from mice bearing
MPC-11, which had a significant increase
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in total spleen lymphocytes following
immunization, show normal amounts of
TdR incorporated after LPS stimulation
(Tables I and III). The presence of some
tumour cells in the preparation oflympho-
cytes from plasmacytoma-bearing mice
may be related to the high basal TdR
incorporation of unstimulated cultures
(Tables II and III). However, it is unlikely
that this elevated TdR incorporation in
unstimulated cultures from plasma-
cytoma-bearing animals is due to the
metabolism of tumour cells, since spleen
imprints show only a small proportion of
the cells to be morphologically identifiable
as tumour cells. Nevertheless, these malig-
nant plasma cells may serve as a constant
antigenic stimulus to the lymphocytes. It
has been shown that in vivo administration
of antigen to normal mice causes transient
inhibition of the PHA response of their
spleen cells in vitro (Gershon et al., 1974).
We are now studying the possible role of
metastatic tumour cells in the impairment
of lymphocytes after mitogenic or anti-
genic stimulation.
Sera from plasmacytoma-bearing mice
do not adversely affect the mitogen
response of lymphocytes to both mitogens
(Table IV and V). The presence ofhumoral
immunosuppressive factors in multiple
myeloma has been proposed (Zolla, 1972;
Zolla et al., 1974); Tanapatchaiyapong
and Zolla, 1974). However, we could find
no evidence of suppressive factor(s) in our
system. Thus, if such a factor exists in
serum from plasmacytoma-bearing mice,
it may be very unstable or present in
ineffective concentrations in the experi-
mental system used. We could not evalu-
ate the effect of higher serum concentra-
tions, as these proved to be inhibitory to
our cultures. However, our results pre-
sented here on the mitogenic response of
lymphocytes from plasmacytoma-bearing
mice suggest a cellular site ofthe defect in
plasmacytoma.
At present, we are continuing our
search for immunosuppressive factors in
the serum, using diffusion chambers in
vivo and serum fractions in vitro. We are
evaluating the response of lymphocytes
from plasmacytoma-bearing animals to
antigenic stimulation in vitro, usingdefined
lymphocyte and monocyte populations.
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